BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1506 related articles for article (PubMed ID: 8899193)

  • 41. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante Hemopoyético.
    Carreras E; Tomás JF; Sanz G; Iriondo A; Boqué C; López J; Cabrera R; Sureda A; de Soria VG; Sierra J; Sanz MA; Torres A
    Haematologica; 2000 May; 85(5):530-8. PubMed ID: 10800172
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hyperfractionated total lymphoid irradiation and cyclophosphamide for preparation of previously transfused patients undergoing HLA-identical marrow transplantation for severe aplastic anemia.
    Castro-Malaspina H; Childs B; Laver J; Shank B; Brochstein J; Gillio A; Flomenberg N; Young J; Boulad F; Black P
    Int J Radiat Oncol Biol Phys; 1994 Jul; 29(4):847-54. PubMed ID: 8040033
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Allogeneic bone marrow transplantation for chronic myeloid leukemia: a single center experience.
    Vela-Ojeda J; Tripp-Villanueva F; Sánchez-Cortés E; Ayala-Sánchez M; Rosas-Cabral A; Esparza MG; García-Chávez J; García-León LD; González-Llaven J
    Arch Med Res; 2000; 31(2):206-9. PubMed ID: 10880729
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia.
    Hessner MJ; Endean DJ; Casper JT; Horowitz MM; Keever-Taylor CA; Roth M; Flomenberg N; Drobyski WR
    Blood; 1995 Nov; 86(10):3987-96. PubMed ID: 7579370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.
    Socié G; Stone JV; Wingard JR; Weisdorf D; Henslee-Downey PJ; Bredeson C; Cahn JY; Passweg JR; Rowlings PA; Schouten HC; Kolb HJ; Klein JP
    N Engl J Med; 1999 Jul; 341(1):14-21. PubMed ID: 10387937
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
    Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
    Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recipients of HLA-identical sibling marrow transplants with severe aplastic anemia engraft more quickly, and those with chronic myeloid leukemia more slowly, than those with acute leukemia.
    Atkinson K; Downs K; Ashby M; Dodds A; Concannon A; Biggs J
    Bone Marrow Transplant; 1989 Jan; 4(1):23-7. PubMed ID: 2647183
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukemia.
    Mackinnon S; Barnett L; Heller G; O'Reilly RJ
    Blood; 1994 Jun; 83(11):3409-16. PubMed ID: 8193379
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term follow-up of patients after related- and unrelated-donor bone marrow transplantation for chronic myelogenous leukemia.
    Reiter E; Greinix HT; Keil F; Brugger S; Rabitsch W; Schulenburg A; Mannhalter C; Schwarzinger I; Worel N; Volc-Platzer B; Fischer G; Dieckmann K; Hinterberger W; Schneider B; Haas OA; Geissler K; Kalhs P
    Ann Hematol; 1999 Nov; 78(11):507-13. PubMed ID: 10602894
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Allogeneic bone marrow transplantation for fourteen patients with severe aplastic anemia.
    Hsueh EJ; Hwang WS; Huang SH; Chao TY; Chang JY; Wang CC
    Zhonghua Yi Xue Za Zhi (Taipei); 1996 Apr; 57(4):247-53. PubMed ID: 8705875
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia.
    Drobyski WR; Pelz C; Kabler-Babbitt C; Hessner M; Baxter-Lowe LA; Keever-Taylor CA
    Biol Blood Marrow Transplant; 1998; 4(1):3-12. PubMed ID: 9701386
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Allogeneic bone marrow transplantation for leukemia with marrow grafts depleted of lymphocytes by counterflow centrifugation.
    Schattenberg A; De Witte T; Preijers F; Raemaekers J; Muus P; Van der Lely N; Boezeman J; Wessels J; Van Dijk B; Hoogenhout J
    Blood; 1990 Mar; 75(6):1356-63. PubMed ID: 2310832
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Different outcomes between cyclophosphamide plus horse or rabbit antithymocyte globulin for HLA-identical sibling bone marrow transplant in severe aplastic anemia.
    Atta EH; de Sousa AM; Schirmer MR; Bouzas LF; Nucci M; Abdelhay E
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1876-82. PubMed ID: 22796534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia.
    Drobyski WR; Ash RC; Casper JT; McAuliffe T; Horowitz MM; Lawton C; Keever C; Baxter-Lowe LA; Camitta B; Garbrecht F
    Blood; 1994 Apr; 83(7):1980-7. PubMed ID: 8142664
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia.
    Bejanyan N; Kim S; Hebert KM; Kekre N; Abdel-Azim H; Ahmed I; Aljurf M; Badawy SM; Beitinjaneh A; Boelens JJ; Diaz MA; Dvorak CC; Gadalla S; Gajewski J; Gale RP; Ganguly S; Gennery AR; George B; Gergis U; Gómez-Almaguer D; Vicent MG; Hashem H; Kamble RT; Kasow KA; Lazarus HM; Mathews V; Orchard PJ; Pulsipher M; Ringden O; Schultz K; Teira P; Woolfrey AE; Saldaña BD; Savani B; Winiarski J; Yared J; Weisdorf DJ; Antin JH; Eapen M
    Blood Adv; 2019 Oct; 3(20):3123-3131. PubMed ID: 31648332
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Donor chimerism does not predict response to donor lymphocyte infusion for relapsed chronic myelogenous leukemia after allogeneic hematopoietic cell transplantation.
    Chiorean EG; DeFor TE; Weisdorf DJ; Blazar BR; McGlave PB; Burns LJ; Brown C; Miller JS
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):171-7. PubMed ID: 14993882
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Bone marrow transplantation for severe aplastic anemia.
    Storb R; Champlin RE
    Bone Marrow Transplant; 1991 Aug; 8(2):69-72. PubMed ID: 1933061
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [A clinical study of 19 cases of unrelated heterogenic bone marrow transplantation].
    Xu L; Huang X; Ren H; Zhang Y; Guo N; Lu D
    Zhonghua Nei Ke Za Zhi; 2002 Apr; 41(4):256-8. PubMed ID: 12133439
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 76.